Payment overview · 2025
General Payments
$538.52
26 reported records · 16 companies
Healthcare provider profile · identity verified
Jeevana Krishna, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CUMMING, GA · NPI 1528020575
Verified facts
What the public records show
CMS Open Payments records show Jeevana Krishna, M.D. received $538.52 in general payments during 2025 across 26 reported records.
GlaxoSmithKline, LLC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.47 | 17.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.59 | 13.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.53 | 12.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.89 | 6.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.83 | 5.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.95 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.22 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.94 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.07 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.77 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.93 | 4.1% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $21.92 | 4.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.08 | 3.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.83 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.80 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.70 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.52 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $98.54 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $94.47 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $74.43 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.53 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 294 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 212 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 89 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 49 |
| Gabapentin | Gabapentin | 156 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 71 |
| Prednisone | Prednisone | 154 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 60 |
| Lisinopril | Lisinopril | 119 | 55 |
| Omeprazole | Omeprazole | 113 | 50 |
| Losartan Potassium | Losartan Potassium | 107 | 48 |
| Tramadol Hcl | Tramadol Hcl | 102 | 34 |
| Metformin Hcl | Metformin Hcl | 92 | 49 |
| Baclofen | Baclofen | 85 | 48 |
| Azithromycin | Azithromycin | 83 | 74 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 42 |
| Meloxicam | Meloxicam | 82 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 25 |
| Furosemide | Furosemide | 62 | 27 |
| Lorazepam | Lorazepam | 60 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | 15 |
| Simvastatin | Simvastatin | 56 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 27 |
| Clonazepam | Clonazepam | 51 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 35 |
| Trazodone Hcl | Trazodone Hcl | 46 | 19 |
| Famotidine | Famotidine | 45 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 21 |
| Pregabalin | Pregabalin | 42 | 22 |
| Promethazine Hcl | Promethazine Hcl | 42 | 13 |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 20 |
| Ondansetron Odt | Ondansetron | 39 | 27 |
| Sertraline Hcl | Sertraline Hcl | 39 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 13 |
| Glipizide | Glipizide | 34 | 20 |
| Montelukast Sodium | Montelukast Sodium | 34 | 19 |
| Temazepam | Temazepam | 34 | 12 |
| Diazepam | Diazepam | 33 | 11 |
| Ozempic | Semaglutide | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 15 |
| Atenolol | Atenolol | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 12 |
| Eliquis | Apixaban | 29 | 14 |
| Fluconazole | Fluconazole | 28 | 12 |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | 12 |
| Estradiol | Estradiol | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 14 |
| Allopurinol | Allopurinol | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Levofloxacin | Levofloxacin | 22 | 22 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | 11 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Naproxen | Naproxen | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 15 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.52 · 26 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, CAPLYTA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Fibroscan, INSPIRE, Leqembi, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System, XIFAXAN, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error